MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer

01 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

25 1 2023 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2023 15:05:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

06 1 2023 06:00:18 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

22 12 2022 15:05:10 提供 Nasdaq GlobeNewswire

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

14 12 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 12 2022 15:05:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Jefferies London Healthcare Conference

08 11 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

07 11 2022 06:00:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 11 2022 15:05:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

31 10 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

06 10 2022 15:05:37 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 10 2022 15:05:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

30 9 2022 07:02:05 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

12 9 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

06 9 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 9 2022 15:05:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers

16 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

08 8 2022 15:04:00 提供 Nasdaq GlobeNewswire

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

08 8 2022 15:02:00 提供 Nasdaq GlobeNewswire